Durvalumab and Stereotactic Radiotherapy for Advanced NSCLC
Status:
Recruiting
Trial end date:
2027-05-01
Target enrollment:
Participant gender:
Summary
This is a randomized Phase II study which is designed to determine the impact of stereotactic
radiotherapy and durvalumab on quality-of-life and oncologic outcomes in patients with
advanced non-small cell lung cancer. Durvalumab (Imfinzi) and stereotactic radiotherapy, with
each fraction of radiotherapy is given every other day on a standard stereotactic ablative
radiotherapy (SAbR) schedule or every four weeks on the personalized ultra-fractionated
stereotactic adaptive radiotherapy (PULSAR) schedule. Subjects will be followed for a period
of 2 years after completion of treatment or until death, whichever occurs first.
Specifically, subjects will be followed at 1, 3, 6, 9, 12, 15, 18, 21, and 24 months
following treatment. After the 2 year follow up, the patient can continue routine follow up
with their physicians, per standard of care. Subjects removed from therapy for unacceptable
adverse events will be followed until resolution or stabilization of the adverse event.